Universal Beteiligungs und Servicegesellschaft mbH Acquires Shares of 50,096 Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH acquired 50,096 shares of Axsome Therapeutics, valued at approximately $5.84 million, during the first quarter, holding about 0.10% of the company after the investment.
• Insider transactions revealed significant sales, including COO Mark L. Jacobson selling 25,000 shares for around $2.76 million and a total of 93,437 shares sold by insiders valued at nearly $9.83 million over three months.
• Analysts have a consensus rating of "Buy" for Axsome Therapeutics, with price targets ranging from $160 to $200 following recent ratings upgrades.

Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 50,096 shares of the company's stock, valued at approximately $5,843,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.10% of Axsome Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of the company. Y Intercept Hong Kong Ltd acquired a new stake in Axsome Therapeutics in the first quarter valued at approximately $1,486,000. IFP Advisors Inc raised its stake in Axsome Therapeutics by 0.4% during the 1st quarter. IFP Advisors Inc now owns 68,114 shares of the company's stock valued at $7,944,000 after purchasing an additional 275 shares during the last quarter. Edgestream Partners L.P. bought a new stake in Axsome Therapeutics in the 1st quarter valued at $8,174,000. New York State Common Retirement Fund grew its holdings in shares of Axsome Therapeutics by 49.3% in the 1st quarter. New York State Common Retirement Fund now owns 33,581 shares of the company's stock worth $3,917,000 after purchasing an additional 11,090 shares during the last quarter. Finally, Mutual of America Capital Management LLC lifted its position in Axsome Therapeutics by 0.3% during the 1st quarter. Mutual of America Capital Management LLC now owns 39,623 shares of the company's stock worth $4,621,000 after buying an additional 136 shares in the last quarter. Institutional investors and hedge funds own 81.49% of the company's stock.

Axsome Therapeutics Stock Up 0.6%

NASDAQ:AXSM traded up $0.63 during trading hours on Thursday, reaching $101.89. The company's stock had a trading volume of 95,650 shares, compared to its average volume of 787,687. The company has a debt-to-equity ratio of 3.48, a current ratio of 2.03 and a quick ratio of 1.96. Axsome Therapeutics, Inc. has a one year low of $72.21 and a one year high of $139.13. The business's 50-day moving average is $105.94 and its 200-day moving average is $110.20. The company has a market cap of $5.02 billion, a price-to-earnings ratio of -17.72 and a beta of 0.46.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Jefferies Financial Group began coverage on shares of Axsome Therapeutics in a research report on Monday, April 7th. They issued a "buy" rating and a $200.00 price target on the stock. Oppenheimer began coverage on Axsome Therapeutics in a research note on Tuesday, June 3rd. They set an "outperform" rating and a $185.00 price objective on the stock. Robert W. Baird lifted their target price on Axsome Therapeutics from $160.00 to $162.00 and gave the company an "outperform" rating in a report on Tuesday, May 6th. Morgan Stanley started coverage on Axsome Therapeutics in a research report on Thursday, July 3rd. They issued an "overweight" rating and a $190.00 price objective for the company. Finally, HC Wainwright restated a "buy" rating and set a $180.00 price target on shares of Axsome Therapeutics in a report on Tuesday, June 10th. One investment analyst has rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $172.33.

Insider Buying and Selling

In related news, COO Mark L. Jacobson sold 25,000 shares of the firm's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $110.44, for a total value of $2,761,000.00. Following the completion of the sale, the chief operating officer owned 5,783 shares of the company's stock, valued at $638,674.52. This trade represents a 81.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, General Counsel Hunter R. Murdock sold 7,500 shares of Axsome Therapeutics stock in a transaction on Tuesday, June 17th. The stock was sold at an average price of $100.26, for a total transaction of $751,950.00. The disclosure for this sale can be found here. Insiders sold 93,437 shares of company stock valued at $9,834,215 over the last quarter. Corporate insiders own 22.30% of the company's stock.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.